The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Open accessAbstract
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently entered the therapeutic armamentarium of clinical oncologists, and show promising activity in patients with breast and other cancers. Although their chief mechanism of action is inhibition of Retinoblastoma (RB) protein phosphorylation and thus induction of cell cycle arrest, CDK4/6 inhibitors alter cancer cell biology in other ways that can also be leveraged for therapeutic benefit. These include modulation of mitogenic kinase signaling, induction of a senescence-like phenotype, and enhancement of cancer cell immunogenicity. Here, we describe the lesser appreciated effects of CDK4/6 inhibitors on cancer cells, and suggest ways by which they might be exploited to enhance the benefits of these agents for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
CDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., López‐Mejía, I. C., Denechaud, P., Escoté, X., Castillo‐Armengol, J., Jiménez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 87
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“In order to enter the cell cycle and commence DNA replication, a cell must pass from the G1 phase into the S phase through a tightly regulated restriction point [7].”
BackgroundTSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“This is not altogether surprising, given the important role RB activation plays in mediating senescence [97, 98].”
BackgroundGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Self-citationNew functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., & Blenis, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.200-216.2004 · Cited by 868
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
A role for both RB and p53 in the regulation of human cellular senescence*1
SHAY, J. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90453-2 · Cited by 757
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F.
Hiebert, S. W., Chellappan, S. P., Horowitz, J. M., & Nevins, J. R. (1992) · Genes & Development · doi:10.1101/gad.6.2.177 · Cited by 576
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Mechanism of active transcriptional repression by the retinoblastoma protein
Weintraub, S. J., Chow, K. N. B., Luo, R. X., Zhang, S. H., He, S., & Dean, D. C. (1995) · Nature · doi:10.1038/375812a0 · Cited by 487
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Self-citationSchaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 376
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Dickson, M. A., Schwartz, G. K., Keohan, M. L., D’Angelo, S. P., Gounder, M. M., Chi, P., Antonescu, C. R., Landa, J., Qin, L.-X., Crago, A. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0264 · Cited by 326
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Induction of cyclin D1 overexpression by activated ras.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J. H., Colombo, L. L., & Conti, C. J. (1994) · PubMed · Cited by 295
Vijayaraghavan, S., Karakas, C., Doostan, I., Chen, X., Bui, T., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 292
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Leboulch, P., Chen, J.-J., Schmidt, E. V., Sonenberg, N., & London, I. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21176 · Cited by 269
Herschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
Deciphering the retinoblastoma protein phosphorylation code
Rubin, S. M. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.007 · Cited by 245
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
Geoerger, B., Bourdeaut, F., DuBois, S. G., Fischer, M., Geller, J. I., Gottardo, N. G., Marabelle, A., Pearson, A. D. J., Modak, S., Cash, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2898 · Cited by 190
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A. U., Sidransky, D., Ewen, M. E., & Rollins, B. J. (1995) · PubMed · Cited by 181
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 167
Chicas, A., Kapoor, A., Wang, X., Aksoy, O., Evertts, A. G., Zhang, M. Q., Garcia, B. A., Bernstein, E., & Lowe, S. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119836109 · Cited by 164
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Wardell, S. E., Ellis, M. J., Alley, H. M., Eisele, K. J., VanArsdale, T. L., Dann, S. G., Arndt, K. T., Primeau, T. M., Griffin, E., Shao, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0360 · Cited by 160
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
Albers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41602-x · Cited by 145
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
Watts, C. K. W., Sweeney, K. J. E., Warlters, A., Musgrove, E. A., & Sutherland, R. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689680 · Cited by 131
Jeselsohn, R. M., Brown, N. E., Arendt, L. M., Klebba, I., Hu, M. G., Kuperwasser, C., & Hinds, P. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.024 · Cited by 130
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123 · cited 1×
“Interestingly, the RAS pathway, like the PI3K pathway, can also activate mTOR through downstream phosphorylation of TSC2 [92, 93] and combined CDK4/6 and MEK inhibition also leads to a synergistic suppression of mTORC1 signaling [94].”
BackgroundWitkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119 · cited 1×
“Examples include combinations of CDK4/6 inhibitors with HER2 inhibitors in breast cancer [5, 69, 70]; PI3K inhibitors in breast cancer, mesothelioma, and mantle cell lymphoma [71–73]; mTOR inhibitors in cancers of the breast or head and neck [74, 75]; IGF-1R inhibitors in pancreatic cancer [76]; and ALK inhibitors in…”
BackgroundCombined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Olmez, I., Brenneman, B. R., Xiao, A., Serbulea, V., Benamar, M., Zhang, Y., Manigat, L. C., Abbas, T., Lee, J., Nakano, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0803 · Cited by 114
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 111
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106
Implications of time-series gene expression profiles of replicative senescence.
Kim, Y., Byun, H., Jee, B. A., Cho, H., Seo, Y., Kim, Y., Park, M. H., Chung, H., Woo, H. G., & Yoon, G. (2013) · Aging Cell · doi:10.1111/acel.12087 · Cited by 106
Bonelli, M. A., Digiacomo, G., Fumarola, C., Alfieri, R. R., Quaini, F., Falco, A., Madeddu, D., Monica, S. L., Cretella, D., Ravelli, A., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.003 · Cited by 104
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Ziemke, E. K., Dosch, J. S., Maust, J. D., Shettigar, A., Sen, A., Welling, T. H., Hardiman, K. M., & Sebolt, J. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0829 · Cited by 102
Erikson, J., Finan, J. B., Tsujimoto, Y., Nowell̀, P. C., & Croce, C. M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.13.4144 · Cited by 101
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Wood, A., Krytska, K., Ryles, H. T., Infarinato, N. R., Sano, R., Hansel, T. D., Hart, L. S., King, F. J., Smith, T. R., Ainscow, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1114 · Cited by 101
Romano, G., Chen, P.-L., Song, P., McQuade, J. L., Liang, R. J., Liu, M., Roh, W., Duose, D. Y., Carapeto, F. C. L., Li, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0745 · Cited by 96
Kim, H. S., Jung, M., Kang, H., Kim, H. R., Park, C. W., Kim, S.-M., Shin, S. J., Kim, S. H., Kim, S. G., Kim, E., et al. (2017) · Oncogene · doi:10.1038/onc.2016.486 · Cited by 94
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 93
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 89
Lundgren, K., Brown, M., Pineda, S., Cuzick, J. M., Salter, J., Zabaglo, L. A., Howell, A., Dowsett, M., Landberg, G., & the TransATAC investigators (2012) · Breast Cancer Research · doi:10.1186/bcr3161 · Cited by 86
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M. E., Chen, L. L., Martínez, D., Li, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1131 · Cited by 86
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium
Brown, N. E., Jeselsohn, R. M., Bihani, T., Hu, M. G., Foltopoulou, P. F., Kuperwasser, C., & Hinds, P. W. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4139 · Cited by 80
Chen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
Teh, J. L. F., Cheng, P. F., Purwin, T. J., Nikbakht, N., Patel, P. S., Chervoneva, I., Ertel, A., Fortina, P. M., Kleiber, I., HooKim, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0699 · Cited by 74
Palbociclib-induced autophagy and senescence in gastric cancer cells
Valenzuela, C. A., Vargas, L., Martinez, V., Bravo, S., & Brown, N. E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.031 · Cited by 73
Negative Regulation of TSC1-TSC2 by Mammalian D-Type Cyclins
Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2236 · Cited by 72
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O. V., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 72
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 72
Self-citationCycD/Cdk4 and Discontinuities in Dpp Signaling Activate TORC1 in the Drosophila Wing Disc
Romero‐Pozuelo, J., Demetriades, C., Schroeder, P., & Teleman, A. A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.07.019 · Cited by 71
Talluri, S., Isaac, C. E., Ahmad, M. A. E.-R., Henley, S. A., Francis, S. M., Martens, A. L., Bremner, R., & Dick, F. A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01168-09 · Cited by 66
Ku, B. M., Yi, S. Y., Koh, J., Bae, Y.-H., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7543 · Cited by 61
Finn, R., Jiang, Y., Rugo, H. S., Moulder, S., Im, S., Gelmon, K. A., Dieras, V. C., Martín, M., Joy, A. A., Toi, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.05 · Cited by 55
Zhou, J., Zhang, S., Chen, X., Zheng, X., Yao, Y., Lu, G., & Zhou, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.031 · Cited by 47
Elaidi, R., Vano, Y.-A., Aide, N., Fournier, L. S., Deandreis, D., Tenenbaum, F., Lebtahi, R., de Clermont-Gallerande, H., Albiges, L. K., Escudier, B. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.80 · Cited by 45
Lu, Y., Boss, J. M., Hu, S. X., Xu, H., & Blanck, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.7.2495 · Cited by 40
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
Stice, J. P., Wardell, S. E., Norris, J. D., Yllanes, A. P., Alley, H. M., Haney, V. O., White, H. S., Safi, R., Winter, P. S., Cocce, K. J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0028 · Cited by 40
Alhaja, E., Adán, J., Pagan, R., Mitjans, F., Cascalló, M., Rodríguez, M., Noé, V., Ciudad, C. J., Mazo, A., Vilaró, S., et al. (2004) · Angiogenesis · doi:10.1007/s10456-005-0368-9 · Cited by 35
Jirawatnotai, S., Sharma, S., Michowski, W., Suktitipat, B., Geng, Y., Quackenbush, J. F., Elias, J. E., Gygi, S. P., Wang, Y. E., & Siciński, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946850 · Cited by 30
Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., Arpino, G., Pavesi, L., Martignetti, A., Criscitiello, C., Puglisi, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1002 · Cited by 13
Rowell, E. A., Wang, L., Chunder, N., Hancock, W. W., & Wells, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091587 · Cited by 10
Cited by
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy
Krug, K., Jaehnig, E. J., Satpathy, S., Blumenberg, L., Karpova, A., Anurag, M., Miles, G., Mertins, P., Geffen, Y., Tang, L. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.036 · Cited by 537
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Self-citationRegulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 372
Metadata
- Authors
- Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 28
- Issue
- 11
- Pages
- 911-925
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W2883876469
- Cited by
- 501
- References
- 119
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.